¹Ì±¹ HDSA¶ó´Â ÇåÆÃÅϺ´ ȯ¿ìȸ ´ÜüÀÇ ¼Ò°³±Û ¿Ã¸³´Ï´Ù.
±Û·Î¹ú Á¦¾à ȸ»ç ÈÀÌÀÚ¿¡¼ ÇåÆÃÅϺ´ óġ ¾à¹°¿¡ ´ëÇÑ ¼Ò°³µîÀ» ¹ßÇ¥ÇÑ´Ù°í ÇÕ´Ï´Ù.
ÇåÆÃÅϺ´¿¡ ´ëÇÑ °ü½ÉÀ̳ª ½ÃÀ强ÀÌ ³·´õ¶óµµ ±¹³» Á¦¾àȸ»çµéµµ °ü½ÉÀ» °¡Áö°í ÀÌ·¯ÇÑ ¾à¿¡ ´ëÇÑ ¼öÀÔ°ú È«º¸¸¦ ÇØÁÖ±æ Èñ¸ÁÇغ¾´Ï´Ù.
RESEARCH WEBINAR REMINDER
Title:
PF-02545920: an Investigational Pfizer Compound for the Treatment of Huntington's Disease
Date:
November 19, 2015
Time: 12-1pm EST
Presenter:
Dr. Ottavio Vitolo, Medical Director, Pfizer
The purpose of this study is to find out if the investigational drug PF-02545920 is safe and if it will have beneficial effects in participants with HD. The study will measure the effects of the new drug developed by Pfizer on movements, mental abilities and behavior in people with HD. Dr. Vitolo will present on the rationale and study design of this currently recruiting HD clinical trial.
|
|
|